A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Nov 5, 2018

Science Based Targets Initiative Approves Astellas’ Greenhouse Gas Reduction Plan

TOKYO, November 5, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the company’s mid-to-long term greenhouse gas (GHG)...

Read more about Science Based Targets Initiative Approves Astellas’ Greenhouse Gas Reduction Plan
Oct 31, 2018

Astellas Announces Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies

TOKYO, October 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that construction and renovation of new facilities for the...

Read more about Astellas Announces Construction of New Research, Development and Manufacturing Facilities for Drugs Using Innovative Modalities/Technologies Including Antibodies and Cell Therapies
Oct 30, 2018

ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and San Francisco, October 30, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more about ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
Oct 29, 2018

Astellas Receives European Approval for XTANDI™ (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs. 14.7 months for men who received placebo plus ADT

TOKYO, October 29, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the European Commission (EC) has approved a new indication...

Read more about Astellas Receives European Approval for XTANDI™ (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Oct 23, 2018

Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App

TOKYO , October 23, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and BANDAI NAMCO Entertainment Inc. (President and CEO: Satoshi Oshita,...

Read more about Astellas and BANDAI NAMCO Entertainment to Jointly Develop Smartphone Exercise Support App
Oct 9, 2018

Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library

TOKYO and OSAKA, October 9, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), Mitsubishi Tanabe Pharma Corporation (TSE: 4508, President and CEO:...

Read more about Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS®", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
Oct 5, 2018

CYTOKINETICS AND ASTELLAS PROVIDE UPDATES REGARDING COLLABORATIVE SKELETAL MUSCLE PROGRAM

SOUTH SAN FRANCISCO, Calif., and TOKYO, Oct. 5, 2018 – Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update...

Read more about CYTOKINETICS AND ASTELLAS PROVIDE UPDATES REGARDING COLLABORATIVE SKELETAL MUSCLE PROGRAM
Oct 1, 2018

Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and San Francisco, October 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...

Read more about Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis
Sep 25, 2018

BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

THE FIRST-AND-ONLY BISPECIFIC CD19-DIRECTED CD3 T CELL ENGAGER (BiTE®) IMMUNOTHERAPY

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more about BLINCYTO® FOR DRIP INFUSION 35μg APPROVED IN JAPAN FOR THE TREATMENT OF RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Sep 25, 2018

Astellas Receives Positive CHMP Opinion for XTANDI^TM (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Results from the PROSPER trial show a median metastasis-free survival (MFS) of 36.6 months for enzalutamide plus androgen deprivation therapy (ADT) vs 14.7 months for men who received placebo plus ADT1

TOKYO and CHERTSEY, September 24, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that The Committee for Medicinal Products for...

Read more about Astellas Receives Positive CHMP Opinion for XTANDI^TM (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Sep 21, 2018

Notice of Completion of Acquisition of Own Shares

Read more about Notice of Completion of Acquisition of Own Shares
Sep 21, 2018

Astellas Announces Approval in Japan for XOSPATA® 40 mg Tablets for the Treatment of FLT3mut+ Relapsed or Refractory AML

TOKYO, September 21, 2018 -Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that XOSPATA® Tablets 40 mg (generic name: gilteritinib), a...

Read more about Astellas Announces Approval in Japan for XOSPATA® 40 mg Tablets for the Treatment of FLT3mut+ Relapsed or Refractory AML
Sep 20, 2018

Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anemia not on Dialysis

TOKYO, September 20, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that roxadustat, an inhibitor of hypoxia ¬inducible factor...

Read more about Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anemia not on Dialysis
Sep 18, 2018

Astellas Announces Launch of Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

TOKYO, September 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has launched Dafclir® Tablets 200 mg (generic name:...

Read more about Astellas Announces Launch of Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan
Sep 14, 2018

Gene Therapy Research Institution and Astellas Executes Option Agreement for Sporadic ALS Gene Therapy Program

TOKYO, September 14, 2018 –Gene Therapy Research Institution Co., Ltd. (head office: Kawasaki, Kanagawa; President: Katsuhito Asai, “GTRI”) and Astellas Pharma Inc. (TSE: 4503, head office:...

Read more about Gene Therapy Research Institution and Astellas Executes Option Agreement for Sporadic ALS Gene Therapy Program
Sep 3, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Aug 23, 2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer - Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials -

NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced amendments to the...

Read more about Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer - Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials -
Aug 21, 2018

Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

TOKYO and CAMBRIDGE, Mass August 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD ,...

Read more about Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
Aug 10, 2018

Astellas Announces Acquisition of Quethera - Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma -

TOKYO, CAMBRIDGE (UK), August 10, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., “Astellas”) and Quethera Limited (CEO: Peter Widdowson, Ph.D.,...

Read more about Astellas Announces Acquisition of Quethera - Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma -
Aug 3, 2018

Application for Supplemental Indication Filed for Hypercholesterolemia Drug Repatha® SC Injection in Treating Statin-intolerant Patients

Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...

Read more about Application for Supplemental Indication Filed for Hypercholesterolemia Drug Repatha® SC Injection in Treating Statin-intolerant Patients
Aug 1, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Jul 17, 2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) - First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC -

TOKYO and NEW YORK, July 13, 2018 –Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug...

Read more about U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) - First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC -
Jul 10, 2018

Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced...

Read more about Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Jul 2, 2018

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Jul 2, 2018

Astellas Received Approval for Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan

TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of...

Read more about Astellas Received Approval for Dafclir® Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan
Jun 29, 2018

Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalutamide) in Men with Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy

TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which...

Read more about Results from Pivotal Phase 3 PROSPER Trial of XTANDI® (enzalutamide) in Men with Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine
Jun 28, 2018

Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year

Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in...

Read more about Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year
Jun 26, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
Jun 11, 2018

Astellas Announces Launch of XTANDI® Tablets in Japan for the Treatment of Castration-Resistant Prostate Cancer

TOKYO, June 11, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched 40 mg XTANDI® (generic name enzalutamide) Tablets and 80...

Read more about Astellas Announces Launch of XTANDI® Tablets in Japan for the Treatment of Castration-Resistant Prostate Cancer
Jun 4, 2018

Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

TOKYO and BOTHELL, Wash. – June 3, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced...

Read more about Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Jun 1, 2018

Astellas Announces Personnel Change

Astellas Announces Personnel Change

Read more about Astellas Announces Personnel Change
May 31, 2018

Astellas Announces Acquisition of Own Shares

Tokyo, May 31, 2018- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.) today announced that at the meeting of the Board of Directors held today, a resolution was adopted...

Read more about Astellas Announces Acquisition of Own Shares
May 31, 2018

Astellas Submits Application for Approval of Peficitinib for Rheumatoid Arthritis (Including Prevention of Structural Joint Damage) in Patients Who Have an Inadequate Response to Conventional Therapies in Japan

TOKYO, May 31, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has submitted an application for marketing approval of peficitinib...

Read more about Astellas Submits Application for Approval of Peficitinib for Rheumatoid Arthritis (Including Prevention of Structural Joint Damage) in Patients Who Have an Inadequate Response to Conventional Therapies in Japan
May 31, 2018

Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia

TOKYO and San Francisco, May 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, “FibroGen”

Read more about Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia
May 31, 2018

Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving -Cancer Care in Underserved Regions of the World-

TOKYO – May 31, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the launch of the third annual Astellas Oncology C3 Prize...

Read more about Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving -Cancer Care in Underserved Regions of the World-
May 29, 2018

U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

TOKYO – May 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted,...

Read more about U.S. FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 24, 2018

Addition of Mirabegron to Tamsulosin Demonstrates Superior Efficacy Compared to Placebo in Men with Overactive Bladder Symptoms

TOKYO – May 24, 2018 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the post-marketing MATCH study exploring use of mirabegron versus...

Read more about Addition of Mirabegron to Tamsulosin Demonstrates Superior Efficacy Compared to Placebo in Men with Overactive Bladder Symptoms
May 22, 2018

SUJANU® Combination Tablets released -Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor-

Tokyo,May 22,2018 -MSD K.K. (head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (head office: Chuo-ku, Tokyo; President and CEO; Kenji Yasukawa;...

Read more about SUJANU® Combination Tablets released -Drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor-
May 22, 2018

Restructuring of Operations in Japan - Restructuring Astellas Pharma Inc. and group companies in Japan, and offering early retirement incentive program -

TOKYO, May 22, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced restructuring of operations in Japan and introduction of the early...

Read more about Restructuring of Operations in Japan - Restructuring Astellas Pharma Inc. and group companies in Japan, and offering early retirement incentive program -
May 16, 2018

Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

TOKYO – May 16, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that a wide selection of abstracts highlighting the...

Read more about Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2018

Partial Amendments to the Articles of Incorporation

Read more about Partial Amendments to the Articles of Incorporation
May 11, 2018

Notice Regarding the Performance-linked Stock Compensation Scheme

Read more about Notice Regarding the Performance-linked Stock Compensation Scheme
May 10, 2018

Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan

VANCOUVER, British Columbia, May 9, 2018 and TOKYO, Japan, May 10, 2018 – Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP, “Aquinox”), a clinical-stage pharmaceutical company discovering and...

Read more about Aquinox and Astellas Announce Exclusive Licensing Agreement for Rosiptor in the Asia-Pacific Region Including Japan
May 8, 2018

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms

TOKYO, May 7, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Read more about FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms
Apr 26, 2018

Astellas Announces Cancellation of Treasury Shares

Read more about Astellas Announces Cancellation of Treasury Shares
Apr 26, 2018

Astellas Reports Financial Results for FY2017

Read more about Astellas Reports Financial Results for FY2017
Apr 26, 2018

Astellas Announces Director Candidates after the Transition to a Company with an Audit & Supervisory Committee

Read more about Astellas Announces Director Candidates after the Transition to a Company with an Audit & Supervisory Committee
Apr 24, 2018

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

TOKYO, April 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it submitted on March 23, 2018, a new drug application...

Read more about Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
Apr 18, 2018

Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

TOKYO, April 18, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, “Astellas” ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, “Kite”)...

Read more about Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company
Mar 29, 2018

Astellas to Participate in “Neglected Tropical Diseases Drug Discovery Booster” Consortium with DNDi and Seven Other Pharmaceutical Companies

Tokyo, March 29, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced an agreement for collaborative research with the Drugs for Neglected Diseases...

Read more about Astellas to Participate in “Neglected Tropical Diseases Drug Discovery Booster” Consortium with DNDi and Seven Other Pharmaceutical Companies

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts